InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.87%
)
US TECH 100
16,798.40
(
0.27%
)
Dow Jones
38,239.98
(
0.67%
)
Brent Oil
87.19
(
0.90%
)
Bitcoin
66,114.17
(
-1.11%
)
Post# of 22812
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

$Pistol Pete$

Send PM Follow Ignore
Followers 2543
Posts 250731
Boards Moderated 34
Alias Born 05/06/2014

$Pistol Pete$

Re: None

Friday, 06/29/2018 12:52:26 AM

Friday, June 29, 2018 12:52:26 AM

Post# of 22812
$MNKD “We are pleased to have completed the TreT Phase 1 trial, which met the study’s safety, tolerability and pharmacokinetics objectives,” stated David Kendall, Chief Medical Officer of MannKind. “We are excited to utilize our existing technology platform and device capabilities to create an easy-to-use and tolerable formulation of treprostinil to help unmet patient needs in a serious chronic disease such as PAH.”

https://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29+Completes+Phase+1+Trial+of+Treprostinil+Technosphere+for+PAH+Advancing+Development+to+Next+Phase/14283663.html


investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up